Abstract
Introduction

Advances in analytic techniques have allowed for the characterization of synthetic peptides, and the utility of various synthetic peptides has been investigated in clinical trials of the treatment of cancers, infectious diseases and endocrine diseases. Synthetic peptides have been widely used for clinical trials to treat intractable human diseases such as cancers, infectious diseases and endocrine diseases
. Unlike retrovirus vectors, synthetic peptides have little chance to integrate or recombinate to host genome, and can be analysed for purity and fidelity of sequencing using well-established analytical techniques [2] .
One class of antimicrobial peptides possesses both antimicrobial and proinflammatory activities and can modulate human immune system activity [4] [5] [6] . These peptides exhibit potent killing of a broad range of micro-organisms and serve as a first-line defence system as well as interact with host repair and adaptive immune responses [7] , and levels of these peptides are increased in the context of inflammation and injury [8, 9] . Major [10, 11] . PR-39 is an anti-microbial peptide of the porcine cathelicidin family and induces angiogenesis by inhibiting the ubiquitin-proteasome-dependent degradation of HIF-1␣ [10] . The human cathelicidin family molecule, LL-37/hCAP18, is a 37-amino acid peptide beginning with two leucine residues that forms a linear amphipathic ␣-helix and that possesses a broad spectrum of antimicrobial activity [11] . [12] . Thus, some antimicrobial peptides can also stimulate angiogenesis.
Further, LL-37/hCAP18 acts as a chemoattractant of neutrophils, monocytes and T cells and promotes angiogenesis by binding to a G-protein-coupled receptor upstream of the PLC-␥/PKC/NFkB, ERK-1 and 2 MAPK, and the PI3K/Akt pathways
We recently screened a human cDNA library in an attempt to isolate angiogenic factors and successfully identified a powerful and potent angiogenic cDNA clone (p3743) [13] . Further analysis of the angiogenic clone facilitated the identification of a core sequence of EC growth activity. Interestingly, in silico analysis showed that the peptide from the core sequence (MLSLIFLHRLKSMRKRLDRKLRLWHRKNYP) was predicted to form an a-helical structure with a high percentage hydrophobic residues, a structure that is characteristic of various antimicrobial peptides [4] [5] [6] 
Materials and methods
Peptide synthesis and circular dichroism (CD) spectroscopy analysis
Synthetic AG-30 (NH2 -MLSLIFLHRLKSMRKRLDRKLRLWHRKNYP-COOH) and control peptide (NH2 -RSLEGTDRFPFVRLKNSRKLEFKDIKGIKR-COOH)
were purchased from Peptide Institute, Inc. (Osaka, Japan). Control peptide and LL-37 were synthesized as per a previous report [12] and purchased from SIGMA Genosys (Hokkaido, Japan) .
CD data were acquired with Jasco J-820 Spectropho-tometer using a 1-mm path length cuvette [14] . Spectra were collected for samples of 50 M AG- 30 and control (Ctrl) 
Minimal inhibitory concentration (MIC) assays
MIC assays were conducted as previously described [15] 
In vivo Matrigel plug assay
Two different types of Matrigel plug assays were performed as previously described [17] . 
Preparation of gelatin microspheres incorporating AG-30
The carboxyl groups of gelatin with an isoelectric point of 5.0 (MW 100,000) were prepared from pig skin by an acid process (Nitta gelatin Inc., Osaka, Japan) and were chemically converted by introducing amino groups for cationization of gelatin as previously described [19] . [22] in Fig. 1A) . To follow and give a better impression of the environment of each amino acid widely separated by the unfolding of the cylinder, hydrophobic residues were encircled, demonstrating sets of adjacent hydrophobic residues in hydrophobic clusters (Fig. 1B) . Of note, there were very few proline or glycine residues that would otherwise interrupt the ␣-helical structure. The structure of this peptide is reminiscent of that of some antimicrobial peptides that directly interact with bacterial membranes. (Fig. 1C) 
Antimicrobial effect of AG-30
Angiogenic property of AG-30
Some antibacterial peptides also possess angiogenic properties. (Fig. 3A) . Further, these results were reproduced using another type of matrigel assay (DIVAA), and quantification by FITC-lectin staining showed that treatment with AG-30 significantly increased neovessels with a potency that was superior to that of LL-37 (Fig. 3B) . In combination with the results demonstrated above, these data suggest that AG-30 induces angiogenesis via increased endothelial cell and smooth muscle cell migration and invasion. 
In a human endothelial cell viability assay, AG-30 increased MTS activity in a dose-dependent (from 0.1 to 1.0 g/ml) manner, and was more potent than LL-37 (Fig. 2A). Treatment with AG-30 also increased vascular smooth muscle cell viability in a dose-dependent manner (from 0.1 to 1.0 g/ ml), as assessed by MTS assay (Fig. 2B). Human cell lines, such as HEK293, SAS (tongue cancer), HuH7 (hepatoma) and HeLa (cervical cancer) did not show significant response in viability in response to AG-30 stimulation (data not shown). In addition, chemokinetic cell migration significantly increased in response to AG-30 (which was more potent than LL-37) but not in response to control peptide (Fig. 2C). We have also addressed the chamotactic action of AG-30 by the addition of AG-30 in the lower chambers and HAEC in the upper chambers. As a result, the treatment of AG-30 with HAEC showed not only chemokinetic migration but also chemotactic action (Fig. 2D), although the chemokinetic action of AG-30 was stronger than chemotactic action. Further, tube formation was greater in response to AG-30 treatment when compared with LL-37 or control peptide treatment (Fig. 2E). These data demonstrate that AG-30 was superior to LL-37 in terms of inducing endothelial cell growth, migration and tube formation. The in vivo angiogenic activity of AG-30 has been evaluated by an established mouse Matrigel plug assay [23]. Matrigel, containing either control peptide or AG-30, was subcutaneously injected into male C57BL/6 mice. Seven days later, neovessels containing intact red blood cells were more numerous in mice that received Matrigel plug containing AG-30 than in mice receiving Matrigel plug containing control peptide. The increased presence of neovessels in the AG-30-treated group relative to the other groups was confirmed by immunostaining with anti-CD31 and anti-asmooth muscle actin antibody
Microarray and real-time PCR Analysis in AG-30-treated endothelial cells
Discussion
The present study demonstrated that a novel small peptide, AG-30, induced angiogenesis by promoting the expression of diverse angiogenic molecules. AG-30 was predicted to belong to a family of antimicrobial peptides that function to protect the host organisms against a large variety of invading pathogens [4] [5] [6] . These peptides are usually highly amphipathic molecules with hydrophobic and hydrophilic moieties segregating into distinct domains on the molecule surface.
In response to a bacterial membrane, AG-30 transforms to an ␣-helix structure and disrupts the membrane via a lytic effect. By contrast, the eucaryotic membrane does not induce a change in AG-30 structure change into an ␣-helix. Cholesterol, which is an essential component in the eucaryotic cell membrane, prevents self-damage of endogenous antimicrobial peptides [24] . This differential phenomenon underlies the ability of AG-30 to kill bacteria while simultaneously promoting endothelial cell growth. Defensins and cathelicidin families are well known as antimicrobial peptides, which are related to angiogenesis. Defensin contains 6-8 cysteine residues that form characteristic disulfide 
